Ameriprise
RUBY

Ameriprise’s Rubius Therapeutics, Inc RUBY Stock Holding History

Ameriprise’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-93,139
Closed -$513K – 4024
2022
Q1 		$513K Buy
93,139
+10,628
+13% +$67.5K ﹤0.01% 3479
2021
Q4 		$798K Buy
82,511
+22,453
+37% +$311K ﹤0.01% 3354
2021
Q3 		$1.07M Buy
60,058
+6,797
+13% +$148K ﹤0.01% 3140
2021
Q2 		$1.3M Buy
53,261
+4,838
+10% +$121K ﹤0.01% 3110
2021
Q1 		$1.28M Sell
48,423
-63,381
-57% -$926K ﹤0.01% 3038
2020
Q4 		$848K Sell
111,804
-23,776
-18% -$141K ﹤0.01% 3161
2020
Q3 		$680K Sell
135,580
-85
-0.1% -$450 ﹤0.01% 3133
2020
Q2 		$812K Buy
135,665
+19,711
+17% +$116K ﹤0.01% 3005
2020
Q1 		$517K Buy
115,954
+1,583
+1% +$11.8K ﹤0.01% 3110
2019
Q4 		$1.09M Buy
114,371
+28,841
+34% +$279K ﹤0.01% 3020
2019
Q3 		$672K Sell
85,530
-48,681
-36% -$567K ﹤0.01% 3188
2019
Q2 		$2.11M Buy
134,211
+34,080
+34% +$550K ﹤0.01% 2719
2019
Q1 		$1.81M Buy
100,131
+83,031
+486% +$1.27M ﹤0.01% 2784
2018
Q4 		$275K Buy
+17,100
New +$312K ﹤0.01% 3377

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise's RUBY Position: Q2 2022 in Review

Ameriprise sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 93,139 shares — an estimated $513K sold.

Ameriprise first reported a position in RUBY in Q4 2018 and held it in 14 quarters. The position peaked at $2.11M in Q2 2019. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • Ameriprise reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • Ameriprise sold 93,139 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $513K.
  • Ameriprise first reported a position in Rubius Therapeutics, Inc in Q4 2018 and held it in 14 quarters.
  • Ameriprise's Rubius Therapeutics, Inc position peaked at $2.11M in Q2 2019.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Ameriprise's 13F filing for Q2 2022, filed 15 Aug 2022.